+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilars Market - Global Forecast 2026-2032- Product Image
Biosimilars Market - Global Forecast 2026-2032- Product Image
Sale

Biosimilars Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6083156
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biosimilars Market is projected to reach USD 38.50 Billion in 2026. It is expected to continue growing at a CAGR of 10.73%, reaching USD 71.24 Billion by 2032.

Biosimilars are reshaping biologic drug access by offering highly similar alternatives to approved reference biologics after exclusivity periods expire. Unlike small-molecule generics, biosimilars require extensive analytical, nonclinical, and clinical evidence because biologics are manufactured in living systems and are inherently variable.

Regulatory maturity is driving confidence. The European Medicines Agency approved the first biosimilar in 2006, while the U.S. Food and Drug Administration approved its first biosimilar in 2015 under the Biologics Price Competition and Innovation Act pathway. The World Health Organization has also supported global regulatory convergence through guidance on similar biotherapeutic products. Today, biosimilars are central to strategies focused on oncology, immunology, endocrinology, ophthalmology, nephrology, and supportive care, with adoption shaped by payer incentives, physician trust, manufacturing scale, pharmacovigilance discipline, and patient education.

Transformative Shifts in the Biosimilars Landscape

The biosimilars landscape is shifting from early regulatory validation to competitive commercialization. Multiple biosimilars for high-spend biologics, including adalimumab, trastuzumab, bevacizumab, rituximab, epoetin, filgrastim, pegfilgrastim, and insulin glargine, have demonstrated that biosimilar competition can broaden patient access and pressure biologic spending when reimbursement systems support substitution, tendering, and formulary uptake.

Manufacturers are also moving beyond launch timing and price discounting. Competitive advantage increasingly depends on reliable supply, device usability, interchangeability strategies where applicable, real-world evidence, prescriber education, and lifecycle planning. As biologic patent expirations continue across monoclonal antibodies, fusion proteins, insulins, and complex biologics, organizations with advanced comparability science, global regulatory expertise, and cost-efficient manufacturing networks are better positioned to capture sustained value.

Cumulative Impact of Artificial Intelligence on Biosimilars

Artificial intelligence is creating cumulative gains across the biosimilar value chain rather than replacing regulatory evidence requirements. AI-enabled analytics can support cell-line screening, upstream and downstream process optimization, protein characterization, impurity pattern detection, and batch-to-batch comparability assessment. These capabilities are especially valuable because biosimilar success depends on controlling critical quality attributes, including glycosylation, potency, purity, aggregation, and stability, with high precision.

AI is also improving clinical development and post-market monitoring. Machine learning can identify appropriate patient cohorts, optimize trial operations, detect pharmacovigilance signals, and analyze real-world outcomes from claims, registries, and electronic health records. The impact is strongest when AI systems are validated, auditable, explainable, and aligned with Good Manufacturing Practice, data integrity, cybersecurity, and evolving regulatory expectations for advanced analytics in regulated life sciences environments.

Key Regional Insights for Biosimilars

Asia-Pacific is a major growth engine for biosimilars due to large treatment-naive populations, expanding biologics access, and strong manufacturing bases in India, China, and South Korea. China’s National Medical Products Administration has strengthened biosimilar guidance, India has long-standing similar biologics pathways, and South Korea has built globally recognized biologics manufacturing capabilities. Japan and Australia add regulatory rigor and reimbursement discipline, supporting quality-led adoption across oncology, immunology, diabetes, and supportive care.

North America remains commercially influential, led by the United States and Canada. U.S. biosimilar uptake is shaped by FDA approvals, interchangeability designations, payer contracting, pharmacy benefit dynamics, specialty pharmacy channels, and provider confidence, while Canadian provinces have used switching policies to expand savings and increase biosimilar utilization in publicly funded systems. Europe continues to be the most mature biosimilar environment, supported by EMA experience since 2006, national tenders, therapeutic switching experience, and physician familiarity built through years of post-approval evidence.

Latin America is advancing through ANVISA, COFEPRIS, and other national regulatory frameworks, though access varies by reimbursement capacity, local procurement systems, and public-sector funding. The Middle East is investing in biologics localization, particularly in Saudi Arabia and the UAE, where health-system modernization and procurement reform are improving access to complex medicines. Africa shows long-term potential, with South Africa, Egypt, and Morocco serving as important regulatory and manufacturing reference points as reliance mechanisms, WHO-aligned standards, and essential medicine access initiatives evolve.

Key Group Insights Across Global Biosimilar Markets

ASEAN markets are benefiting from gradual regulatory alignment, reliance pathways, and demand for affordable biologics across oncology, diabetes, renal care, and autoimmune disease. Health systems in the region are increasingly using biosimilars to expand treatment access while balancing quality assurance and procurement efficiency. GCC countries are using centralized procurement, formulary management, insurance reform, and health-system modernization to improve biosimilar access while encouraging local biologics capability and supply security.

The European Union remains the benchmark group for biosimilar regulation due to the EMA’s long-standing scientific framework, member-state pharmacovigilance systems, and extensive real-world experience with switching and tender-driven adoption. BRICS economies combine large patient populations with manufacturing ambition, making them central to future biosimilar supply, demand, and localization strategies. G7 markets shape global standards through regulatory science, intellectual property policy, health-technology assessment, reimbursement models, and pharmacovigilance expectations. NATO is not a medicines regulator, but its member economies increasingly view pharmaceutical supply resilience, biologics manufacturing capacity, and medical countermeasure readiness as part of broader health-security planning.

Key Country Insights Shaping Biosimilar Adoption

The United States is the largest commercial battleground for biosimilars, with adoption influenced by payer contracting, FDA interchangeability policy, state substitution laws, specialty pharmacy economics, and the competitive impact of biosimilars for blockbuster biologics. Canada has accelerated uptake through provincial switching initiatives and public drug plan policies, while Mexico and Brazil are expanding biosimilar pathways to address affordability, therapeutic access, and public procurement needs. Brazil’s health regulator has established comparability requirements, and the country’s public health system remains an important channel for biologic access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established biosimilar experience, although tender design, prescribing incentives, hospital procurement, and physician engagement differ by country. Germany has used physician-level prescribing frameworks and rebate mechanisms, the United Kingdom has supported biosimilar uptake through national health-system guidance, and France, Italy, and Spain continue to refine substitution, tendering, and regional access approaches. Russia continues to emphasize domestic biologics production and import substitution to improve medicine security.

China and India are pivotal manufacturing and demand centers, supported by large patient populations, expanding biologics use, and domestic regulatory pathways for similar biologics. Japan prioritizes stringent quality expectations, post-marketing surveillance, and reimbursement controls, while Australia supports biosimilar prescribing through policy incentives and public reimbursement mechanisms. South Korea stands out for export-oriented biosimilar manufacturing, strong bioprocessing capability, and regulatory experience that supports participation in global biosimilar supply chains.

Actionable Recommendations for Biosimilar Industry Leaders

Industry leaders should prioritize scientifically robust comparability packages, scalable manufacturing, and transparent quality systems. Biosimilar success depends on consistent critical quality attributes, regulatory readiness across multiple jurisdictions, and a launch strategy that addresses payer, physician, pharmacist, and patient concerns before market entry.

Organizations should invest in real-world evidence, pharmacovigilance infrastructure, device and administration improvements, cold-chain resilience, and supply continuity planning. Partnerships with local manufacturers, distributors, contract development and manufacturing organizations, and health systems can accelerate access in emerging markets. Leaders should also prepare for intensified price competition by differentiating on reliability, service support, education, portfolio breadth, and therapeutic depth rather than discounting alone.

Research Methodology

This executive summary is developed through secondary research and analytical synthesis using verified public sources, including regulatory agency records, biosimilar approval databases, health-technology assessment guidance, policy documents, peer-reviewed literature, pharmacovigilance guidance, and publicly available reimbursement and tender information. Key reference points include FDA, EMA, WHO, national regulatory authorities, public health agencies, and published real-world evidence sources.

The methodology evaluates market dynamics across regulation, manufacturing, commercialization, therapeutic application, geographic adoption, procurement policy, and competitive behavior. Insights are validated by cross-checking regulatory milestones, approval trends, policy actions, reimbursement decisions, and real-world adoption signals. The analysis avoids speculative claims and emphasizes evidence-based interpretation of biosimilar market development without market sizing, market share estimates, or forecasting.

Conclusion

Biosimilars are moving from a cost-containment tool to a strategic pillar of biologic medicine access. The strongest opportunities are emerging where regulatory clarity, manufacturing reliability, payer alignment, prescriber confidence, and patient support reinforce one another.

Future leadership will be defined by organizations that combine advanced analytical science, efficient production, AI-enabled process intelligence, disciplined pharmacovigilance, and region-specific commercialization models. As more biologic exclusivities expire, biosimilars are expected to play a larger role in improving affordability, expanding treatment access, and strengthening global biologics supply resilience.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Biosimilars Market, by Product Type
7.1. Introduction
7.2. Monoclonal Antibodies
7.2.1. Anti-TNF Agents
7.2.2. Anti-CD20 Agents
7.2.3. Anti-VEGF Agents
7.3. Recombinant Hormones & Growth Factors
7.3.1. Insulin & Analogues
7.3.2. Granulocyte Colony-Stimulating Factors
7.3.3. Erythropoiesis-Stimulating Agents
7.4. Fusion Proteins
7.5. Peptides
8. Biosimilars Market, by Therapeutic Area
8.1. Introduction
8.2. Oncology
8.2.1. Breast Cancer
8.2.2. Colorectal Cancer
8.2.3. Lung Cancer
8.2.4. Hematologic Malignancies
8.3. Autoimmune & Inflammatory
8.3.1. Rheumatoid Arthritis
8.3.2. Psoriasis & Psoriatic Arthritis
8.3.3. Inflammatory Bowel Disease
8.3.3.1. Crohns Disease
8.3.3.2. Ulcerative Colitis
8.3.4. Ankylosing Spondylitis
8.4. Endocrinology & Metabolism
8.5. Hematology
8.5.1. Neutropenia
8.5.2. Chemotherapy-Induced Anemia
8.6. Fertility & Reproductive Health
8.7. Ophthalmology
8.8. Neurology
9. Biosimilars Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Subcutaneous
9.4. Intramuscular
10. Biosimilars Market, by Development Stage
10.1. Introduction
10.2. Discovery & Preclinical
10.3. Clinical Development
10.3.1. Phase I
10.3.2. Phase II
10.3.3. Phase III
10.4. Regulatory & Approval
10.5. Commercialization
11. Biosimilars Market, by Manufacturing Technology
11.1. Introduction
11.2. Recombinant DNA Technology
11.3. Cell Culture Systems
11.4. Microbial Expression Systems
11.4.1. Escherichia Coli
11.4.2. Yeast
11.5. Protein Purification & Formulation
11.6. Analytical & Characterization Platforms
12. Biosimilars Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Clinics
12.4. Research & Academic Institutes
12.5. Homecare Settings
13. Biosimilars Market, by Distribution Channel
13.1. Introduction
13.2. Online
13.3. Offline
14. Biosimilars Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Biosimilars Market, by Group
15.1. NATO
15.2. G7
15.3. BRICS
15.4. European Union
15.5. ASEAN
15.6. GCC
16. Biosimilars Market, by Country
16.1. United States
16.2. China
16.3. Japan
16.4. Germany
16.5. India
16.6. United Kingdom
16.7. France
16.8. Canada
16.9. Australia
16.10. Italy
16.11. Brazil
16.12. South Korea
16.13. Mexico
16.14. Russia
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Alvotech S.A
18.2. Amgen Inc.
18.3. Apobiologix
18.4. Apotex Inc.
18.5. Biocon Limited
18.6. BioFactura, Inc.
18.7. Biogen Inc.
18.8. Boehringer Ingelheim International GmbH
18.9. Catalent, Inc
18.10. Celltrion Healthcare Co.,Ltd.
18.11. Coherus BioSciences
18.12. Dr. Reddy's Laboratories Limited
18.13. Eden Biologics, Inc.
18.14. F. Hoffmann-La Roche AG
18.15. Fresenius Kabi
18.16. Innovent Biologics, Inc.
18.17. Intas Pharmaceuticals Ltd.
18.18. Kashiv BioSciences, LLC.
18.19. Merck KGaA
18.20. NeuClone
18.21. Nippon Kayaku Co., Ltd.
18.22. Novartis AG
18.23. Panacea Biotec Limited
18.24. Pfizer Inc.
18.25. Samsung Bioepis Co., Ltd.
18.26. Sanofi S.A.
18.27. Shanghai Henlius Biotech, Inc.
18.28. Teva Pharmaceutical Industries Ltd.
18.29. Thermo Fisher Scientific, Inc.
List of Figures
FIGURE 1. GLOBAL BIOSIMILARS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BIOSIMILARS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BIOSIMILARS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BIOSIMILARS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ANTI-TNF AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ANTI-TNF AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ANTI-TNF AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ANTI-CD20 AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ANTI-CD20 AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ANTI-CD20 AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL RECOMBINANT HORMONES & GROWTH FACTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL RECOMBINANT HORMONES & GROWTH FACTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL RECOMBINANT HORMONES & GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL INSULIN & ANALOGUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL INSULIN & ANALOGUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL INSULIN & ANALOGUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL GRANULOCYTE COLONY-STIMULATING FACTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL GRANULOCYTE COLONY-STIMULATING FACTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL GRANULOCYTE COLONY-STIMULATING FACTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ERYTHROPOIESIS-STIMULATING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ERYTHROPOIESIS-STIMULATING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ERYTHROPOIESIS-STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL FUSION PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL FUSION PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PSORIASIS & PSORIATIC ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PSORIASIS & PSORIATIC ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PSORIASIS & PSORIATIC ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CROHNS DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CROHNS DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CROHNS DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ENDOCRINOLOGY & METABOLISM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ENDOCRINOLOGY & METABOLISM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ENDOCRINOLOGY & METABOLISM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL HEMATOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL HEMATOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HEMATOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL NEUTROPENIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL NEUTROPENIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL NEUTROPENIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CHEMOTHERAPY-INDUCED ANEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CHEMOTHERAPY-INDUCED ANEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CHEMOTHERAPY-INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL FERTILITY & REPRODUCTIVE HEALTH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL FERTILITY & REPRODUCTIVE HEALTH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL FERTILITY & REPRODUCTIVE HEALTH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL DISCOVERY & PRECLINICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL DISCOVERY & PRECLINICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL DISCOVERY & PRECLINICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL PHASE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PHASE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL PHASE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL REGULATORY & APPROVAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL REGULATORY & APPROVAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL REGULATORY & APPROVAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL COMMERCIALIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL COMMERCIALIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL COMMERCIALIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL CELL CULTURE SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL CELL CULTURE SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL CELL CULTURE SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL MICROBIAL EXPRESSION SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL MICROBIAL EXPRESSION SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL MICROBIAL EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL YEAST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL YEAST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL YEAST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL PROTEIN PURIFICATION & FORMULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL PROTEIN PURIFICATION & FORMULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL PROTEIN PURIFICATION & FORMULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL ANALYTICAL & CHARACTERIZATION PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL ANALYTICAL & CHARACTERIZATION PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL ANALYTICAL & CHARACTERIZATION PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 183. EUROPE BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 184. EUROPE BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 185. EUROPE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 186. EUROPE BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 187. EUROPE BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 188. EUROPE BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 189. EUROPE BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 190. EUROPE BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 191. EUROPE BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 192. EUROPE BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 193. EUROPE BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 194. EUROPE BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 195. EUROPE BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 196. EUROPE BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 197. EUROPE BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. EUROPE BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 199. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 200. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 201. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 202. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 203. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 204. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 205. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 206. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 207. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 208. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 209. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 210. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 211. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 212. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 213. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 215. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 216. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 217. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 218. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 219. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 220. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 221. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 222. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 223. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 224. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 225. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 226. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 227. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 228. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 229. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 230. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. AFRICA BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 232. AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 233. AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 234. AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 235. AFRICA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 236. AFRICA BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 237. AFRICA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 238. AFRICA BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 239. AFRICA BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 240. AFRICA BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. AFRICA BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 242. AFRICA BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 243. AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 244. AFRICA BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 245. AFRICA BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. AFRICA BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 247. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 248. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 249. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 250. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 251. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 252. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 253. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 254. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 255. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 256. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 257. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 258. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 259. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 260. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 261. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 264. NATO BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 265. NATO BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 266. NATO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 267. NATO BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 268. NATO BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 269. NATO BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 270. NATO BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 271. NATO BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 272. NATO BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 273. NATO BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 274. NATO BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 275. NATO BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 276. NATO BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 277. NATO BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 278. NATO BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. NATO BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 280. G7 BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 281. G7 BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 282. G7 BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 283. G7 BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 284. G7 BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 285. G7 BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 286. G7 BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 287. G7 BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 288. G7 BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 289. G7 BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 290. G7 BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 291. G7 BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 292. G7 BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 293. G7 BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 294. G7 BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. G7 BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 296. BRICS BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 297. BRICS BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 298. BRICS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 299. BRICS BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 300. BRICS BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 301. BRICS BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 302. BRICS BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 303. BRICS BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 304. BRICS BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 305. BRICS BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 306. BRICS BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 307. BRICS BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 308. BRICS BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 309. BRICS BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 310. BRICS BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 311. BRICS BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 312. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 319. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 320. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 321. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 322. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 323. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 324. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 325. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 326. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 327. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 328. ASEAN BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 329. ASEAN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 330. ASEAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 331. ASEAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 332. ASEAN BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 333. ASEAN BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 334. ASEAN BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 335. ASEAN BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 336. ASEAN BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 337. ASEAN BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 338. ASEAN BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 339. ASEAN BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 340. ASEAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 341. ASEAN BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 342. ASEAN BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 343. ASEAN BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 344. GCC BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 345. GCC BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 346. GCC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 347. GCC BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 348. GCC BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 349. GCC BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 350. GCC BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 351. GCC BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 352. GCC BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 353. GCC BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 354. GCC BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 355. GCC BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 356. GCC BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 357. GCC BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 358. GCC BIOSIMILARS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 359. GCC BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 360. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 361. UNITED STATES BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 362. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 363. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 364. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 365. UNITED STATES BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 366. UNITED STATES BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 367. UNITED STATES BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 368. UNITED STATES BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE

Companies Mentioned

  • Alvotech S.A
  • Amgen Inc.
  • Apobiologix
  • Apotex Inc.
  • Biocon Limited
  • BioFactura, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc
  • Celltrion Healthcare Co.,Ltd.
  • Coherus BioSciences
  • Dr. Reddy's Laboratories Limited
  • Eden Biologics, Inc.
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi
  • Innovent Biologics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Kashiv BioSciences, LLC.
  • Merck KGaA
  • NeuClone
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Shanghai Henlius Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific, Inc.

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 38.5 Billion
Forecasted Market Value ( USD ) by 2032 $ 71.24 Billion
Compound Annual Growth Rate10.7%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032 - Product Image

Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Biologics & Biosimilars CXO Services Market - Global Forecast 2026-2032 - Product Image

Biologics & Biosimilars CXO Services Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Biosimilar Contract Manufacturing - Global Strategic Business Report - Product Image

Biosimilar Contract Manufacturing - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Biosimilar Market Size, Share, Trends and Forecast by Molecule, Indication, Manufacturing Type, and Region, 2026-2034 - Product Image

Biosimilar Market Size, Share, Trends and Forecast by Molecule, Indication, Manufacturing Type, and Region, 2026-2034

  • Report
  • 148 Pages
  • Global
From
Biosimilars Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035) - Product Image

Biosimilars Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

  • Report
  • 350 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.